Liver cancer biomarkers and application thereof

Abstract

The invention relates to biomarkers miR-182-5p, miR-363-3p and miR-378a-3p which are beneficial to liver cancer diagnosis, as well as application thereof for preparing kits for screening liver cancer or assisting pathological identification and clinical diagnosis of liver cancer. The kit comprises a reverse transcription system and a primer system, wherein the reverse transcription system comprises reverse transcriptase, a reverse transcription system buffer and an RNA enzyme inhibitor; and the primer system consists of the stem-loop structure reverse transcription primers and amplification primers of miR-182-5p, miR-363-3p and miR-378a-3p and the amplification primers of U6 snRNA. The close correlation between the miRNA and clinical case indexes of liver cancer, determined by the invention, can serve as a biomarker to be used for screening and diagnosing liver cancer, an effective basis is provided for clinical individualized intervention treatment. The biomarker has the advantages of high quantification accuracy, convenience in clinical application, convenience in material preparation and noninvasiveness and can be used for continuous in-vitro detection.

Description

technical field [0001] The invention belongs to the fields of biotechnology and medicine, and relates to a group of biomarkers for hepatocellular carcinoma—microRNAs (miR-182-5p, miR-363-3p, miR-378a-3p), and their role in assisting individual liver cancer screening , clinical diagnosis and prognosis. Background technique [0002] In my country, primary liver cancer is one of the most common malignant tumors, and more than 85% of primary liver cancers are caused by hepatitis B or C virus infection, long-term alcohol abuse and aflatoxin B1 intake. Due to the lack of effective clinical prevention, detection and treatment methods, most patients are diagnosed with advanced cancer, and the prognosis is poor and the mortality rate is high. According to the latest statistics, about 750,000 new liver cancer patients are added every year in the world, and about 700,000 people die from liver cancer every year, and the mortality rate of patients ranks third among all malignant tumors....

AI Technical Summary

Problems solved by technology

In clinical examination, AFP (Alpha-Fetoprotein) is used as a commonly used serological marker for the diagnosis of liver cancer, but its sensitivity and specificity are not satisfactory. Only about 70% of liver cancer patients have significantly increased AFP in the serum, and those with a diameter of less than 3cm The sensitivity is only 25% for tumors larger than 3 cm, and only 50% for tumors larger than 3 cm in diameter

Images